(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are AFFLUENT MEDICAL, BIOSENIC, and ENVIPCO.

Financial Asset	Price	Change	Updated (EST)
AFFLUENT MEDICAL (AFME.PA)	1.56	45.79%	2023-09-14 12:46:01
BIOSENIC (BIOS.BR)	0.03	12.4%	2023-09-14 12:06:05
ENVIPCO (ENVI.AS)	2.40	8.11%	2023-09-14 12:02:02
ADOCIA (ADOC.PA)	10.94	7.68%	2023-09-14 12:45:49
ONWARD MEDICAL (ONWD.BR)	3.98	6.7%	2023-09-14 12:21:07
MOREFIELD GROUP (MORE.AS)	0.33	6.45%	2023-09-14 12:03:17
FOUNTAIN (FOU.BR)	1.40	6.06%	2023-09-14 12:07:14
BELYSSE GROUP (BELYS.BR)	0.85	5.72%	2023-09-14 12:06:01
THUNDERBIRD (TBIRD.AS)	0.10	5.56%	2023-09-14 12:04:45
EVS BROADC.EQUIPM. (EVS.BR)	27.10	5.45%	2023-09-14 12:07:03

The three biggest losers today are CELYAD ONCOLOGY, MITHRA, and GLINTT.

Financial Asset	Price	Change	Updated (EST)
CELYAD ONCOLOGY (CYAD.BR)	0.59	-12.98%	2023-09-14 12:06:20
MITHRA (MITRA.BR)	2.00	-9.59%	2023-09-14 12:20:48
GLINTT (GLINT.LS)	0.32	-9.5%	2023-09-14 12:23:48
BENEVOLENTAI (BAI.AS)	0.93	-7.5%	2023-09-14 12:01:01
NEPI ROCKCASTLE (NRP.AS)	5.50	-6.78%	2023-09-14 12:03:26
AUBAY (AUB.PA)	37.40	-5.67%	2023-09-14 12:46:56
EQVA (EQVA.OL)	2.74	-5.52%	2023-09-14 12:26:54
MOTORK (MTRK.AS)	1.90	-5%	2023-09-14 12:03:19
GEOJUNXION (GOJXN.AS)	0.83	-4.17%	2023-09-14 12:02:29
IDEX BIOMETRICS (IDEX.OL)	0.53	-3.46%	2023-09-14 12:40:42

Winners today

1. AFFLUENT MEDICAL (AFME.PA)

45.79% Price Change

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.

CAC 40 ended the session with AFFLUENT MEDICAL jumping 45.79% to €1.56 on Thursday, after two sequential sessions in a row of gains. CAC 40 rose 1.19% to €7,308.67, after two sequential sessions in a row of losses, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, AFFLUENT MEDICAL has a trailing twelve months EPS of €-0.82.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.36%.

More news about AFFLUENT MEDICAL.

2. BIOSENIC (BIOS.BR)

12.4% Price Change

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with BIOSENIC rising 12.4% to €0.03 on Thursday while BEL 20 rose 1.35% to €3,689.75.

Earnings Per Share

As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.02.

Volatility

BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.54%, a negative 2.76%, and a positive 5.90%.

BIOSENIC’s highest amplitude of average volatility was 13.15% (last week), 6.95% (last month), and 5.90% (last quarter).

Volume

Today’s last reported volume for BIOSENIC is 1245970 which is 256.02% above its average volume of 349965.

More news about BIOSENIC.

3. ENVIPCO (ENVI.AS)

8.11% Price Change

Envipco Holding N.V., together with its subsidiaries, designs, develops, manufactures, and sells or leases reverse vending machines (RVM) for the collection and processing of used beverage containers primarily in the Netherlands, North America, and Europe. The company provides technical support, RVM maintenance, and accounting services to the retail stores, bottlers, and distributors for containers redeemed through its machines. It also offers deposit, handling fees, scrap reconciliations, commodity brokerage, clearing house functions, and accounting services. In addition, the company provides materials handling services primarily in the northeastern part of the United States. Envipco Holding N.V. was incorporated in 1998 and is headquartered in Amersfoort, the Netherlands.

AEX-Index ended the session with ENVIPCO jumping 8.11% to €2.40 on Thursday while AEX-Index rose 1.3% to €744.46.

Earnings Per Share

As for profitability, ENVIPCO has a trailing twelve months EPS of €-0.18.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.87%.

Moving Average

ENVIPCO’s worth is under its 50-day moving average of €2.51 and way below its 200-day moving average of €2.85.

More news about ENVIPCO.

4. ADOCIA (ADOC.PA)

7.68% Price Change

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

CAC 40 ended the session with ADOCIA rising 7.68% to €10.94 on Thursday while CAC 40 jumped 1.19% to €7,308.67.

Earnings Per Share

As for profitability, ADOCIA has a trailing twelve months EPS of €-0.92.

Yearly Top and Bottom Value

ADOCIA’s stock is valued at €10.94 at 22:40 EST, way higher than its 52-week high of €6.62.

More news about ADOCIA.

5. ONWARD MEDICAL (ONWD.BR)

6.7% Price Change

Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.

BEL 20 ended the session with ONWARD MEDICAL jumping 6.7% to €3.98 on Thursday, after three successive sessions in a row of losses. BEL 20 jumped 1.35% to €3,689.75, after two consecutive sessions in a row of losses, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-1.01.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.44%.

Yearly Top and Bottom Value

ONWARD MEDICAL’s stock is valued at €3.98 at 22:40 EST, below its 52-week low of €4.01.

Revenue Growth

Year-on-year quarterly revenue growth grew by 45.8%, now sitting on 2.15M for the twelve trailing months.

Volatility

ONWARD MEDICAL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.80%, a negative 1.46%, and a positive 1.95%.

ONWARD MEDICAL’s highest amplitude of average volatility was 4.50% (last week), 1.91% (last month), and 1.95% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONWARD MEDICAL’s stock is considered to be overbought (>=80).

More news about ONWARD MEDICAL.

6. MOREFIELD GROUP (MORE.AS)

6.45% Price Change

Morefield Group N.V. through its subsidiary Kersten Groep BV, engages in the selecting, advising, supplying, and maintaining medical aids for physical disability peoples. The company also manufactures orthoses, such as braces and splints. It serves to municipalities, care administration offices, health insurers, and care institutions/care organizations. The company was formerly known as HeadFirst Source Group N.V. and changed its name to Morefield Group N.V. in January 2019. Morefield Group N.V. was incorporated in 1983 and is headquartered in Willemstad, Curaçao.

AEX-Index ended the session with MOREFIELD GROUP rising 6.45% to €0.33 on Thursday, following the last session’s downward trend. AEX-Index jumped 1.3% to €744.46, after five sequential sessions in a row of losses, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, MOREFIELD GROUP has a trailing twelve months EPS of €0.1.

PE Ratio

MOREFIELD GROUP has a trailing twelve months price to earnings ratio of 3.3. Meaning, the purchaser of the share is investing €3.3 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.06%.

More news about MOREFIELD GROUP.

7. FOUNTAIN (FOU.BR)

6.06% Price Change

Fountain S.A. engages in the sale, rental, and provision of machines for cold and hot drinks made from freeze-dried or grain products in Europe. It provides coffee and cartridge machines, and other beverages machines. The company offers its products through independent distributors. Fountain S.A. was founded in 1972 and is based in Braine-l'Alleud, Belgium.

BEL 20 ended the session with FOUNTAIN jumping 6.06% to €1.40 on Thursday while BEL 20 rose 1.35% to €3,689.75.

Earnings Per Share

As for profitability, FOUNTAIN has a trailing twelve months EPS of €-0.16.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FOUNTAIN’s stock is considered to be oversold (<=20).

More news about FOUNTAIN.

8. BELYSSE GROUP (BELYS.BR)

5.72% Price Change

Belysse Group NV produces and sells textile floor coverings for commercial and residential applications in Europe, North America, and internationally. The company designs, manufactures, and distributes broadloom carpets and modular carpet tiles primarily for offices and public projects. It commercializes its products under the Bentley, modulyss, arc edition, and ITC brands. The company was formerly known as Balta Group NV and changed its name to Belysse Group NV in October 2022. Belysse Group NV was founded in 1964 and is headquartered in Waregem, Belgium. Belysse Group NV is a subsidiary of LSF9 Belysse Holdco S.à r.l.

BEL 20 ended the session with BELYSSE GROUP jumping 5.72% to €0.85 on Thursday, following the last session’s upward trend. BEL 20 rose 1.35% to €3,689.75, after two successive sessions in a row of losses, on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, BELYSSE GROUP has a trailing twelve months EPS of €-0.42.

Volume

Today’s last reported volume for BELYSSE GROUP is 16019 which is 199.14% above its average volume of 5355.

Volatility

BELYSSE GROUP’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.21%, a negative 1.29%, and a positive 3.47%.

BELYSSE GROUP’s highest amplitude of average volatility was 4.50% (last week), 3.02% (last month), and 3.47% (last quarter).

More news about BELYSSE GROUP.

9. THUNDERBIRD (TBIRD.AS)

5.56% Price Change

Thunderbird Resorts, Inc., through its subsidiaries, engages in the gaming, hospitality, and real estate businesses in Nicaragua and Peru. It provides table and slot games, and sportsbooks. The company operates 3 slot parlors, 3 casinos, and 630 gaming positions. It develops, owns, and operates real estate properties; and rents office spaces. The company was formerly known as International Thunderbird Gaming Corporation and changed its name to Thunderbird Resorts, Inc. in July 2005. Thunderbird Resorts, Inc. was incorporated in 1987 and is headquartered in Panama, the Republic of Panama.

AEX-Index ended the session with THUNDERBIRD jumping 5.56% to €0.10 on Thursday, after four sequential sessions in a row of losses. AEX-Index jumped 1.3% to €744.46, after five successive sessions in a row of losses, on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, THUNDERBIRD has a trailing twelve months EPS of €0.01.

PE Ratio

THUNDERBIRD has a trailing twelve months price to earnings ratio of 9.5. Meaning, the purchaser of the share is investing €9.5 for every euro of annual earnings.

Volume

Today’s last reported volume for THUNDERBIRD is 7000 which is 87.83% below its average volume of 57525.

More news about THUNDERBIRD.

10. EVS BROADC.EQUIPM. (EVS.BR)

5.45% Price Change

EVS Broadcast Equipment SA provides live video technology for broadcast and media productions worldwide. The company offers live replay and storytelling products, including live replay and highlights systems, cloud-based super slow-motion services, and graphics effects; live production, replay, studio production, and software-based studio servers; web-based asset management platform, live PAM suite, achieve digitization and content delivery, media workflow management, and connected archive and transcoding services; and broadcast control and monitoring systems and control panels. It also provides IP router products; real time media processors; media storage systems; production switchers; multi-camera review systems; camera automation systems; and live production systems. In addition, the company offers training and e-learning; cyber security; and support services, such as download area, assistance, support portal, and learning center. Further, it provides solutions in the areas of live sports images, entertainment shows, and news content. The company was incorporated in 1994 and is headquartered in Seraing, Belgium.

BEL 20 ended the session with EVS BROADC.EQUIPM. rising 5.45% to €27.10 on Thursday, after two consecutive sessions in a row of losses. BEL 20 jumped 1.35% to €3,689.75, after two consecutive sessions in a row of losses, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, EVS BROADC.EQUIPM. has a trailing twelve months EPS of €2.65.

PE Ratio

EVS BROADC.EQUIPM. has a trailing twelve months price to earnings ratio of 10.23. Meaning, the purchaser of the share is investing €10.23 for every euro of annual earnings.

Volatility

EVS BROADC.EQUIPM.’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.39%, a positive 0.71%, and a positive 1.27%.

EVS BROADC.EQUIPM.’s highest amplitude of average volatility was 1.57% (last week), 1.65% (last month), and 1.27% (last quarter).

More news about EVS BROADC.EQUIPM..

Losers Today

1. CELYAD ONCOLOGY (CYAD.BR)

-12.98% Price Change

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with CELYAD ONCOLOGY sliding 12.98% to €0.59 on Thursday, after two consecutive sessions in a row of losses. BEL 20 rose 1.35% to €3,689.75, after two sequential sessions in a row of losses, on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.48.

More news about CELYAD ONCOLOGY.

2. MITHRA (MITRA.BR)

-9.59% Price Change

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

BEL 20 ended the session with MITHRA sliding 9.59% to €2.00 on Thursday while BEL 20 jumped 1.35% to €3,689.75.

Earnings Per Share

As for profitability, MITHRA has a trailing twelve months EPS of €-1.22.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -176.58%.

Volume

Today’s last reported volume for MITHRA is 562014 which is 88.93% above its average volume of 297467.

Revenue Growth

Year-on-year quarterly revenue growth grew by 428.6%, now sitting on 67M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MITHRA’s stock is considered to be oversold (<=20).

More news about MITHRA.

3. GLINTT (GLINT.LS)

-9.5% Price Change

Glintt – Global Intelligent Technologies, S.A. provides IT and consulting services in Portugal and internationally. The company offers business consulting services, such as pharmacy management, continuous, diagnostic, and project consulting; and IT consulting services, including applications and technology consulting, business process management, and data analytics. It also provides IT infrastructure services comprising cloud and datacenter, service and application management, networking and security, and information security; physical design and automation, and software solutions; and integrated application and equipment support services. The company primarily serves the healthcare, pharma, financial services, and telecommunications markets, as well as the public sector. Glintt – Global Intelligent Technologies, S.A. was incorporated in 1995 and is based in Sintra, Portugal.

PSI ended the session with GLINTT falling 9.5% to €0.32 on Thursday while PSI rose 1.54% to €6,227.49.

Earnings Per Share

As for profitability, GLINTT has a trailing twelve months EPS of €0.04.

PE Ratio

GLINTT has a trailing twelve months price to earnings ratio of 8.1. Meaning, the purchaser of the share is investing €8.1 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.84%.

Volatility

GLINTT’s last week, last month’s, and last quarter’s current intraday variation average was 1.49%, 1.58%, and 2.66%.

GLINTT’s highest amplitude of average volatility was 3.45% (last week), 3.03% (last month), and 2.66% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

GLINTT’s EBITDA is 12.5.

More news about GLINTT.

4. BENEVOLENTAI (BAI.AS)

-7.5% Price Change

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

AEX-Index ended the session with BENEVOLENTAI falling 7.5% to €0.93 on Thursday, following the last session’s downward trend. AEX-Index rose 1.3% to €744.46, after five successive sessions in a row of losses, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-1.76.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -152.53%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BENEVOLENTAI’s stock is considered to be overbought (>=80).

More news about BENEVOLENTAI.

5. NEPI ROCKCASTLE (NRP.AS)

-6.78% Price Change

NEPI Rockcastle is the premier owner and operator of shopping centres in Central and Eastern Europe (CEE), with presence in nine countries and an investment portfolio of €5.8 billion as at 31 December 2021. The Group benefits from a highly-skilled internal management team which combines asset management, development, investment, leasing and financial expertise. Geographically diverse management skills allow NEPI Rockcastle to pursue CEE property opportunities efficiently, benefiting from a strategic advantage in the acquisition, development and management of properties. NEPI Rockcastle owns and operates 52 retail properties (excluding joint venture) which attracted 244 million visits in 2021 (325 million visits in 2019). With group-level management of tenant relationships and a focus on cross-country collaboration, the Group is the leading strategic partner for major retailers targeting CEE countries. The Group's financial strategy includes maintaining a profile of adequate liquidity, conservative gearing, and a diverse debt structure, which combines secured and unsecured bank debt with unsecured bonds listed on the Irish Stock Exchange. NEPI Rockcastle is investment-grade rated by Standard & Poor's (BBB, stable outlook) and Fitch (BBB, positive outlook). NEPI Rockcastle's shares are listed on the Johannesburg Stock Exchange (“JSE”), Euronext Amsterdam (“Euronext”) and A2X. The Group voluntarily distributes at least 90% of its distributable earnings on a semi-annual basis.

AEX-Index ended the session with NEPI ROCKCASTLE falling 6.78% to €5.50 on Thursday while AEX-Index jumped 1.3% to €744.46.

Earnings Per Share

As for profitability, NEPI ROCKCASTLE has a trailing twelve months EPS of €0.85.

PE Ratio

NEPI ROCKCASTLE has a trailing twelve months price to earnings ratio of 6.47. Meaning, the purchaser of the share is investing €6.47 for every euro of annual earnings.

Volatility

NEPI ROCKCASTLE’s last week, last month’s, and last quarter’s current intraday variation average was 7.89%, 1.24%, and 3.97%.

NEPI ROCKCASTLE’s highest amplitude of average volatility was 7.89% (last week), 4.58% (last month), and 3.97% (last quarter).

More news about NEPI ROCKCASTLE.

6. AUBAY (AUB.PA)

-5.67% Price Change

Aubay Société Anonyme provides application services in Belgium, Luxembourg, Spain, Portugal, Italy, France, and the United Kingdom. The company offers consulting; digital experience services, such as service design thinking/design strategist, UX design/UX digital designer, UI design/UI digital designer, and product management/product owner digital; smart automation/intelligent process automation services, including audit and business process optimization, process mining, OCR and intelligent document processing, NLP and NLU, and machine learning/deep learning; and agility services, such as maturity audit, training and support, and operational agility. It also provides application services; data and analytics services comprising data governance, data platform, data science, and Dataviz and business intelligence; cybersecurity services, such as governance, risk, compliance consulting, project and development security, and secure architecture; cloud infrastructure; and test and automation services. It serves banking/finance, public, health, energy, distribution, insurance, industry, network/telecoms, and services/utilities sectors. Aubay Société Anonyme was incorporated in 1944 and is based in Boulogne-Billancourt, France.

CAC 40 ended the session with AUBAY falling 5.67% to €37.40 on Thursday, after four sequential sessions in a row of losses. CAC 40 rose 1.19% to €7,308.67, after two consecutive sessions in a row of losses, on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, AUBAY has a trailing twelve months EPS of €2.67.

PE Ratio

AUBAY has a trailing twelve months price to earnings ratio of 14.01. Meaning, the purchaser of the share is investing €14.01 for every euro of annual earnings.

Volatility

AUBAY’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.21%, a negative 0.24%, and a positive 1.58%.

AUBAY’s highest amplitude of average volatility was 1.21% (last week), 1.14% (last month), and 1.58% (last quarter).

More news about AUBAY.

7. EQVA (EQVA.OL)

-5.52% Price Change

Eqva ASA, a knowledge-based maritime company, primarily engages in the shipbuilding business worldwide. It operates in two segments, Shipbuilding Technology and Other. The company provides newbuilding, rebuilding, and service assignments on vessels for offshore oil production, renewable energy production, fishing, and fish farming for ship owners. It delivers technology for customers within the seafood, energy, and transport sectors. The company was formerly known as Havyard Group ASA and changed its name to Eqva ASA in November 2022. Eqva ASA was founded in 1999 and is headquartered in Fosnavåg, Norway.

Oslo Børs Benchmark Index_GI ended the session with EQVA dropping 5.52% to €2.74 on Thursday, after three successive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 1.86% to €1,297.20, following the last session’s downward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, EQVA has a trailing twelve months EPS of kr-0.32.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.45%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 209.8%, now sitting on 594.65M for the twelve trailing months.

Volatility

EQVA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.73%, a negative 0.21%, and a positive 3.21%.

EQVA’s highest amplitude of average volatility was 2.79% (last week), 2.86% (last month), and 3.21% (last quarter).

Volume

Today’s last reported volume for EQVA is 2465 which is 81.57% below its average volume of 13378.

More news about EQVA.

8. MOTORK (MTRK.AS)

-5% Price Change

MotorK plc, together with its subsidiaries, provides software-as-a-service for the automotive retail industry in Italy, Spain, France, and Germany. The company offers a combination of automotive SaaS products and digital solutions to the digital lead generation, management, and nurturing process. It provides technology and software solutions for car manufacturers, dealers, and service centers. The company offers WebSparK, a web platform for traffic acquisition and lead generation performance; LeadSparK, a CRM platform to support the activities of car dealerships and automotive manufacturers; and StockSparK, a stock management platform. The company was incorporated in 2010 and is headquartered in Milan, Italy.

AEX-Index ended the session with MOTORK falling 5% to €1.90 on Thursday while AEX-Index jumped 1.3% to €744.46.

Earnings Per Share

As for profitability, MOTORK has a trailing twelve months EPS of €-0.36.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -25.18%.

Volume

Today’s last reported volume for MOTORK is 2251 which is 77.93% below its average volume of 10203.

Volatility

MOTORK’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.34%, a negative 0.17%, and a positive 1.60%.

MOTORK’s highest amplitude of average volatility was 1.00% (last week), 1.23% (last month), and 1.60% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 29.5%, now sitting on 43.54M for the twelve trailing months.

Moving Average

MOTORK’s worth is below its 50-day moving average of €2.10 and under its 200-day moving average of €1.98.

More news about MOTORK.

9. GEOJUNXION (GOJXN.AS)

-4.17% Price Change

GeoJunxion N.V. manufactures and supplies digital maps, premium location content, and location intelligence services worldwide. The company provides location aware content products, including Digital Maps for use in routing, planning, and display services; Geo Location application programming interface (API) that addresses geocoding and time zones covering Europe and North America; and Geo Planning API, which provides time and distance matrices for logistics and resource planning applications, as well as premium location content products, such as Safety Alert Zone that concentrates on road safety by alerting mobility users; Eco Alert Zones, which includes dataset of regulated congestion, emission and restricted traffic zones for use in routing, planning, fleet management, display, real estate applications, and other sectors; and Health Alert Zones that contains COVID-19 related information. It also offers location intelligence services, which includes search and evaluation of location enabled content to enhance existing maps and/or routing applications; creating bespoke datasets; and producing outdoor venue plans for use in events, travel and tourism, real estate applications, last mile navigation and delivery, retail and distribution, and smart city applications, as well as operates GeoAlertsLive application. The company was formerly known as AND International Publishers N.V. GeoJunxion N.V. was founded in 1984 and is headquartered in Capelle aan den IJssel, the Netherlands.

AEX-Index ended the session with GEOJUNXION falling 4.17% to €0.83 on Thursday while AEX-Index rose 1.3% to €744.46.

Earnings Per Share

As for profitability, GEOJUNXION has a trailing twelve months EPS of €-0.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.12%.

Moving Average

GEOJUNXION’s value is way under its 50-day moving average of €0.97 and way below its 200-day moving average of €1.22.

Volatility

GEOJUNXION’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.13%, a positive 0.27%, and a positive 3.77%.

GEOJUNXION’s highest amplitude of average volatility was 5.18% (last week), 5.49% (last month), and 3.77% (last quarter).

Yearly Top and Bottom Value

GEOJUNXION’s stock is valued at €0.83 at 22:40 EST, way under its 52-week high of €1.85 and above its 52-week low of €0.78.

More news about GEOJUNXION.

10. IDEX BIOMETRICS (IDEX.OL)

-3.46% Price Change

IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless financial payment, access control, and smart cards, as well as card-based devices for the storage of digital currencies. It primarily serves manufacturers of smart cards for financial payment applications and biometric payment card markets. The company was incorporated in 1996 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with IDEX BIOMETRICS falling 3.46% to €0.53 on Thursday while Oslo Børs Benchmark Index_GI jumped 1.86% to €1,297.20.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-0.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -141.4%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 32%, now sitting on 4.7M for the twelve trailing months.

Moving Average

IDEX BIOMETRICS’s value is way below its 50-day moving average of kr0.66 and way under its 200-day moving average of kr0.87.

More news about IDEX BIOMETRICS.

Stay up to date with our winners and losers daily report